Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$86.18 - $99.03 $212,692 - $244,406
-2,468 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$89.43 - $102.27 $220,713 - $252,402
2,468 New
2,468 $240,000
Q4 2019

Feb 14, 2020

SELL
$86.8 - $118.57 $1.07 Million - $1.46 Million
-12,354 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$83.82 - $101.5 $1.04 Million - $1.25 Million
12,354 New
12,354 $1.11 Million
Q2 2019

Aug 14, 2019

SELL
$72.24 - $91.27 $843,763 - $1.07 Million
-11,680 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$69.31 - $91.53 $809,540 - $1.07 Million
11,680 New
11,680 $1.03 Million
Q4 2018

Feb 14, 2019

SELL
$68.32 - $124.36 $1.66 Million - $3.03 Million
-24,345 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$98.88 - $125.85 $2.41 Million - $3.06 Million
24,345 New
24,345 $2.99 Million
Q2 2018

Aug 14, 2018

SELL
$75.3 - $105.99 $1.11 Million - $1.56 Million
-14,713 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$75.88 - $92.43 $1.47 Million - $1.8 Million
-19,432 Reduced 56.91%
14,713 $1.22 Million
Q4 2017

Feb 14, 2018

BUY
$58.53 - $77.59 $500,841 - $663,937
8,557 Added 33.44%
34,145 $2.65 Million
Q3 2017

Nov 14, 2017

BUY
$47.97 - $61.28 $1.23 Million - $1.57 Million
25,588
25,588 $1.57 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $11.7B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Paloma Partners Management CO Portfolio

Follow Paloma Partners Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Paloma Partners Management CO with notifications on news.